CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

Impact · against what's priced in

CG Oncology is positioned for a potential valuation rerating based on exceptional durability and safety data for cretostimogene, combined with a clear BLA submission timeline. While the data presents a competitive threat to Merck and Johnson & Johnson in the bladder cancer space, the impact on those mega-caps is negligible due to their diversified portfolios.

CGON+0.70

No priced-in read yet